---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-380215"
form_type: "8-K"
ticker: "ATTO"
cik: "0002058707"
company_name: "Attovia Therapeutics, Inc."
filed_at: "2026-09-02T20:17:18+00:00"
generated_at: "2026-09-02T20:18:24.758204+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Attovia Q2 2026 net loss $20.7M; ATTO-1310 proof-of-concept; IPO funds runway to 2030

## Summary
- Q2 2026 net loss $20.7M vs $14.4M year ago; R&D $18.9M vs $13.6M; collaboration revenue $0.5M.
- Cash $115.1M at 6/30/26; plus $305.4M net IPO proceeds (Aug '26) extends runway into 2030.
- ATTO-1310 Phase 1b shows rapid itch relief in chronic pruritus and high-itch AD; full data Q4 2026.
- Phase 2 studies in CPUO and high-itch AD planned 1H 2027; Phase 1 for ATTO-2306/1091 also 1H 2027.
- IPO gross proceeds $332.4M; board strengthened with John W. Smither appointment.

## SEC filing metadata
- accession: 0001193125-26-380215
- form_type: 8-K
- ticker: ATTO
- cik: 0002058707
- company_name: Attovia Therapeutics, Inc.
- filed_at: 2026-09-02T20:17:18+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/2058707/000119312526380215/0001193125-26-380215-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/2058707/000119312526380215/atto-20260902.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-380215
- JSON: https://secwatch.observer/filing/0001193125-26-380215.json
- Plain text: https://secwatch.observer/filing/0001193125-26-380215.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.